Health Canada Approves Quantum BioPharma’s Qlarity To Support Energy, Endurance, And Cognitive Health

Quantum BioPharma Ltd., a biopharmaceutical company developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, announced that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. The approval enables the company to market Qlarity in Canada, expanding its presence beyond the U.S., where a similar dietary supplement is sold under the brand name unbuzzd™.

“This is a milestone in Quantum BioPharma’s mission to bring innovative products to the market. We can now sell Qlarity to the Canadian market, leveraging its significant potential to improve consumer well-being”, said Mr. Zeeshan Saeed, CEO of Quantum BioPharma. 

With this license, Health Canada authorizes Qlarity for multiple recommended uses. These include supporting energy production and metabolism, maintaining normal electrolyte balance, and temporarily enhancing physical energy, endurance, and motor performance. Additionally, the product is approved to help reduce fatigue, improve mental alertness, and boost cognitive performance.

“I am delighted that the Natural Health Products Directorate at Health Canada has provided a Product License for Qlarity. I look forward to the launch of Qlarity in Canada, offering a solution to support energy, metabolism, mental alertness and cognitive performance”, said Professor Lakshmi P. Kotra, a board director at Quantum BioPharma, a professor of medicinal chemistry at University of Toronto, and a senior scientist at the Krembil Research Institute, University Health Network. 

This milestone strengthens Quantum BioPharma’s portfolio of innovative biotech solutions, aligning with its broader mission to address difficult-to-treat conditions. By leveraging regulatory approvals across regions, the company is positioning Qlarity as a health-supportive product with potential benefits in both physical and mental performance.